<DOC>
	<DOCNO>NCT00000639</DOCNO>
	<brief_summary>To evaluate effectiveness safety amphotericin B plus flucytosine ( 5-fluorocytosine ) compare amphotericin B alone first episode acute cryptococcal meningitis AIDS patient , compare effectiveness safety fluconazole versus itraconazole . At least 10 percent patient low CD4 count HIV infection develop meningitis due Cryptococcus neoformans . More effective treatment standard therapy need explore .</brief_summary>
	<brief_title>A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine Amphotericin B Alone Followed Comparison Fluconazole Itraconazole Treatment Acute Cryptococcal Meningitis</brief_title>
	<detailed_description>At least 10 percent patient low CD4 count HIV infection develop meningitis due Cryptococcus neoformans . More effective treatment standard therapy need explore . Patients select randomization process take amphotericin B intravenously ( vein ) , 14 day , either placebo ( ineffective substance ) flucytosine 14 day . Then patient select randomization process take either ( 1 ) fluconazole total 8 week plus itraconazole placebo ; ( 2 ) itraconazole total 8 week plus fluconazole placebo .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Cryptococcal</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Flucytosine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Interruption myelosuppressive therapy and/or administration erythropoietin , discretion investigator , maintain hemoglobin = &gt; 7 g/dl . Adjunctive corticosteroid may administer triazole phase patient develop Pneumocystis carinii pneumonia meet prescribed criterion . Hydrocortisone , exceed 50 mg/day , amphotericin phase . Aerosolized pentamidine systemic chemoprophylaxis Pneumocystis carinii pneumonia give patient CD4 count &lt; 200 cells/mm3 . Antiretroviral drug ( include zidovudine ( AZT ) , didanosine ( ddI ) , dideoxycytidine ( ddC ) ) patient tolerate oral triazole one week ( 3 week study treatment ) . Maintenance treatment ( except rifamycins ) opportunistic infection cytomegalovirus ( CMV ) retinitis , cerebral toxoplasmosis mycobacterial infection , provide hematologic hepatic value stable meet entry criterion . Concurrent Treatment : Allowed : Transfusion , discretion investigator , maintain hemoglobin = &gt; 7 g/dl . Patients must : HIV infection . Primary episode acute cryptococcal meningitis . Willing participate study full 10 week either able give inform consent family member guardian able give inform consent . Prior Medication : Allowed : Fluconazole prophylaxis , exceed 200 mg/day . Risk Behavior : Allowed : History highrisk behavior HIV infection ( bisexual homosexual men , intravenous drug abuser ) sexual partner . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Inability take oral medication ( necessary , flucytosine flucytosine placebo may administer via nasogastric tube amphotericin phase ) . History hypersensitivity imidazole triazole compound . Active hepatitis ( viral , druginduced , ) define progressive worsening hepatic enzyme grade 3 4 toxicity least two occasion . Comatose . Concurrent CNS disease , opinion investigator , would interfere assessment response . Concurrent Medication : Excluded : Continued treatment H2 blocker ( ranitidine ( Zantac ) , cimetidine ( Tagamet ) , omeprazole ( Prilosec ) , nizatidine ( Axid ) , famotidine ( Pepcid ) ) . Antacids didanosine ( ddI ) within 2 hour triazole administration . Rifampin , rifabutin ( Ansamycin ) , rifamycin derivative , phenytoin ( Dilantin ) , phenobarbital , carbamazepine ( Tegretol ) . Other systemic antifungal agent . Prior Medication : Excluded : Amphotericin , &gt; 1 mg/kg , fluconazole ketoconazole , &gt; 1200 mg , prior treatment current primary episode acute cryptococcal meningitis treatment start episode 72 hour prior enrollment study . Phenytoin ( Dilantin ) , carbamazepine ( Tegretol ) , phenobarbital , rifabutin ( Ansamycin ) , rifampin rifamycins within last 15 day . Patients may : Inability take oral medication ( necessary , flucytosine flucytosine placebo may administer via nasogastric tube amphotericin phase ) . History hypersensitivity imidazole triazole compound . Active hepatitis . Patients comatose . Concurrent CNS disease , opinion investigator , would interfere assessment response .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Meningitis</keyword>
	<keyword>Cryptococcosis</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Fluconazole</keyword>
	<keyword>Flucytosine</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Amphotericin B</keyword>
	<keyword>Brain Diseases</keyword>
</DOC>